Pharmacyclics Grabs Another $50M In Milestones From J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
The Sunnyvale-based biotech has received $100 million in milestone payments from its Big Pharma partner for a mid/late stage oncology drug that could be best-in-class.
You may also be interested in...
Pharmacyclic’s Co-Development Pact With Janssen Carries Largest Single-Asset Upfront Payment Of 2011
The two companies will co-develop and co-commercialize PCI-32765, which is being investigated in multiple types of hematological cancer.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.